search
Back to results

Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa

Primary Purpose

Placenta Previa

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Placebo
Nifedipine
Sponsored by
University Hospital, Rouen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Placenta Previa

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Placenta previa is diagnosed when the lowest placental edge is located within 5 cm of the internal os at ultrasonography
  • Placenta previa may be symptomatic with at least one episode of bleeding
  • Estimated gestational age within 24 to 34 weeks
  • Maternal age > 18 years
  • Informed consent after received an explanation of the study and an information sheet
  • Social affiliation

Exclusion Criteria:

  • Premature rupture of membranes
  • Severe bleeding requiring an immediate termination of pregnancy
  • Abnormal fetal heart rates requiring an immediate termination of pregnancy
  • Intrauterine fetal death
  • Pre-eclampsia, chorioamnionitis, liver disease, severe chronic renal disease, heart disease
  • Abruptio placentae
  • Nifedipine sensibility
  • Drugs interaction with nifedipine

Sites / Locations

  • University Hospital Rouen

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

A

B

Arm Description

Placebo three times daily

20 mg of slow-release Nifedipine three times daily

Outcomes

Primary Outcome Measures

Prolongation of pregnancy

Secondary Outcome Measures

Maternal outcomes i.e number episodes of bleeding, amount of bleeding, number of blood transfusion required

Full Information

First Posted
January 28, 2008
Last Updated
July 9, 2014
Sponsor
University Hospital, Rouen
search

1. Study Identification

Unique Protocol Identification Number
NCT00620724
Brief Title
Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa
Official Title
Maintenance Oral Nifedipine for Management of Symptomatic Placenta Previa : A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
September 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen

4. Oversight

5. Study Description

Brief Summary
The objective of our study is to determine the clinical utility related to the maintenance oral nifedipine therapy in patients with symptomatic placenta previa. This study is a prospective, randomized controlled trial with the inclusion, after 24 weeks gestation, of hospitalized patients with symptomatic placenta praevia. All patients may initially receive oral nifedipine therapy with steroid prophylaxis for 48 hours. After then, patients are randomly assigned to receive either oral nifedipine (20 mg every 8 hours) or placebo (one every 8 hours) until 37 weeks of gestation. The primary outcome for the trial is the length of pregnancy in days after the enrollment. A sample size calculation is designed to detect at least a 14 -day difference in time gained in patients with maintenance oral nifedipine therapy. A sample size of about 52 patients per group would have a 80 % chance of detecting this difference at the 5 % level of significance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Placenta Previa

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
109 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Placebo Comparator
Arm Description
Placebo three times daily
Arm Title
B
Arm Type
Experimental
Arm Description
20 mg of slow-release Nifedipine three times daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo three times daily
Intervention Type
Drug
Intervention Name(s)
Nifedipine
Intervention Description
20 mg of slow-release Nifedipine three times daily
Primary Outcome Measure Information:
Title
Prolongation of pregnancy
Time Frame
From allocation to the delivery
Secondary Outcome Measure Information:
Title
Maternal outcomes i.e number episodes of bleeding, amount of bleeding, number of blood transfusion required
Time Frame
At the end of the study

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Placenta previa is diagnosed when the lowest placental edge is located within 5 cm of the internal os at ultrasonography Placenta previa may be symptomatic with at least one episode of bleeding Estimated gestational age within 24 to 34 weeks Maternal age > 18 years Informed consent after received an explanation of the study and an information sheet Social affiliation Exclusion Criteria: Premature rupture of membranes Severe bleeding requiring an immediate termination of pregnancy Abnormal fetal heart rates requiring an immediate termination of pregnancy Intrauterine fetal death Pre-eclampsia, chorioamnionitis, liver disease, severe chronic renal disease, heart disease Abruptio placentae Nifedipine sensibility Drugs interaction with nifedipine
Facility Information:
Facility Name
University Hospital Rouen
City
Rouen
ZIP/Postal Code
76031
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
35947046
Citation
Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.
Results Reference
derived
PubMed Identifier
28333939
Citation
Verspyck E, de Vienne C, Muszynski C, Bubenheim M, Chanavaz-Lacheray I, Dreyfus M, Deruelle P, Benichou J. Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial. PLoS One. 2017 Mar 23;12(3):e0173717. doi: 10.1371/journal.pone.0173717. eCollection 2017.
Results Reference
derived

Learn more about this trial

Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa

We'll reach out to this number within 24 hrs